We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00524251
Recruitment Status : Completed
First Posted : September 3, 2007
Last Update Posted : September 17, 2008
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)

Condition or disease Intervention/treatment
GERD Quality of Life Drug: esomeprazole

Study Design

Study Type : Observational
Estimated Enrollment : 990 participants
Time Perspective: Prospective
Study Start Date : June 2004
Study Completion Date : March 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with reflux complaints
  • 18 years of age

Exclusion Criteria:

  • Restrictions as mentioned in the registration text
  • H2RA or PPI use in the month prior to inclusion
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524251


  Show 54 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: A Sellink, MD AstraZeneca
Study Chair: N van den Berk AstraZeneca
More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00524251     History of Changes
Other Study ID Numbers: N11
First Posted: September 3, 2007    Key Record Dates
Last Update Posted: September 17, 2008
Last Verified: September 2008

Keywords provided by AstraZeneca:
Patients with reflux complaints
GERD
quality of life
lifestyle adjustments

Additional relevant MeSH terms:
Esomeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action